i&i Biotech Fund
i&i Biotech Fund (i&i Bio) is a Luxembourg-based venture capital firm that invests in innovative European Life Sciences companies focused on drug discoveries, medical devices, diagnostics, and digital health. The fund was established in cooperation with the biotech incubator i&i Prague and the European Investment Fund. With over €53 million under management, i&i Bio plans to invest in about 20 early-stage companies, supporting transformative Central European technology companies.
i&i Biotech Fund
42, rue de la Vallée, L-2661 Luxembourg BP 908 L-2019, Luxembourg
What We Do
i&i Biotech Fund provides financial support to early-stage Life Sciences companies, focusing on drug discoveries, medical devices, diagnostics, and digital health.
The fund offers strategic guidance and mentorship to its portfolio companies, leveraging its experienced team with backgrounds in private equity, healthcare, and venture capital.
i&i Biotech Fund connects its portfolio companies with a network of investors and potential exit partners, facilitating partnerships and collaborations.
The fund provides operational support to its portfolio companies, helping them navigate the challenges of scaling and commercializing their innovations.
Investment Range
Portfolio
Developing small-molecule compounds with anticancer properties, focusing on casein kinase inhibitors.
#Drug Discovery
Leader in label-free, multiplexed biosensing, using photonic integrated circuits to simplify biosensing.
#Biosensing Technology
Developing a breakthrough ambulant diagnostic technology for blood coagulation testing, focusing on hemophilia.
#Diagnostics
Developing a diagnostic platform using genetically engineered cells for single cell analysis.
#Diagnostics
Developing cancer treatments based on unique protein conjugates, focusing on metastatic cancer types.
#Cancer Treatment
Designing antibodies for challenging targets using a machine-learning-centred approach.
#Biotechnology
Develops first-in-class efficacy-enhanced TCR-T cells for solid tumors, using a proprietary TCR-ALLO platform for off-the-shelf treatment.
#Biotechnology
Focused on developing novel therapies for neurological conditions, including a first-in-class EAAT2 Positive Allosteric Modulator for epilepsy.
#Biotechnology
Developing innovative therapies for cardiovascular and metabolic aging, including a pioneering platform for long-acting apelin.
#Biopharmaceutical
Building a high-throughput human organoid cultivation platform for cardiac drug discovery.
#Biotechnology
Developing synthetic polymers for in vitro diagnostics, including SophoMer F10, a polymer that can replace bovine serum albumin in immunoassays.
#Biotechnology
Key People
Partner, Deals
Partner, Deals
Partner, CFO
Communications, Talent Acquisitions
Scientific Analyst